Lomitapide and mipomersen: Novel lipid-lowering agents for the management of familial hypercholesterolemia

Journal of Cardiovascular Nursing

Volumn 29, Issue 5, 2014, Pages

  Dixon, Dave L ^a   Sisson, Evan M ^a   Butler, Michael ^a   Higbea, Ashley ^a   Muoio, Brendan ^a   Turner, Brandy ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Familial hypercholesterolemia; Lomitapide; Mipomersen

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LOMITAPIDE; MIPOMERSEN; OLIGONUCLEOTIDE;

DRUG EFFECTS; ECONOMICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE II; LIVER; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER; OLIGONUCLEOTIDES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84906081702     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0000000000000104     Document Type: Article

References (13)

1. Kolovou GD, Kostakou PM, Anagnostopoulou KK. Familial hypercholesterolemia and triglyceride metabolism. Int J Cardiol. 2010;147(2011):349-358.
2. Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3)(suppl):S18-S29.
3. Hovingh GK, Davidson MH, Kasteleinohn JP, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34(13):962-971.
4. Juxtapid [package insert]. Cambridge, MA: Aegerion Pharmaceuticals Inc; 2012.
5. Cuchel M, Meagher EA, Theron HT, et al. Efficacy and safety of microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a singlearm, open-label, phase 3 study. Lancet. 2013;381(9860):40-46.
6. Cuchel M. Long term, follow-on Study of lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Bethesda, MD: National Library of Medicine (US); 2000. http://clinicaltrials.gov/ct2/show/NCT00943306. NLM Identifier: NCT00943306. Accessed March 15, 2013.
7. Raal F, Santos R, Blom D, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebocontrolled trial. Lancet. 2010;375(9719):998-1006.
8. Visser M, Wagener G, Baker B, Burnett J. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33(9):1142-1149.
9. Kynamro [package insert]. Cambridge, MA: Genzyme Corp; 2013.
10. Stein E, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(9):2283-2292.
11. Genzyme. A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients with Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH). Bethesda, MD: National Library of Medicine (US); 2000. http://clinicaltrials.gov/show/ NCT01475825. NLM Identifier: NCT00943306. Accessed May 30, 2013.
12. Fierce Pharma Web site. www.fiercepharma.com/story/genzymes-176k-kynamro- price-undercuts-its-250k-plus-rival/2013-01-31. Accessed May 22, 2013.
13. US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2011.